Vitamin D and Fatty Liver Disease: A Clinical Trial in Egypt

Effect of Vitamin D Supplementation on Steatosis in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomized Controlled Trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

PACTR

Registry ID

PACTR202509709405673

Enrollment

Registered

2025-09-10

Start date

2022-08-17

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Digestive System

Interventions

vitamin D intervention

controll group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion: Adults with metabolic dysfunction-associated steatotic liver disease, aged 18–60 years

Exclusion criteria

Exclusion criteria: Patients with other chronic liver diseases, significant alcohol consumption, or contraindications to vitamin D therapy.

Design outcomes

Primary

Measure	Time frame
Improvement in hepatic steatosis assessed by fibroscan and lab analysis after 3 months.	—

Secondary

Measure	Time frame
Changes in ALT, AST, and metabolic profile.	—

Countries

Egypt

Contacts

Public Contactwael soliman

lecturer of gastroenterology hepatology and infectious Department Faculty of Medicine Minia University

ali.esmael@mu.edu.eg01032132661

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026